A novel selective peroxisome proliferator-activator receptor-γ modulator-SPPARγM5 improves insulin sensitivity with diminished adverse cardiovascular effects

European Journal of Pharmacology

Volumn 584, Issue 1, 2008, Pages 192-201

  Chang, Ching H ^a   McNamara, Lesley A ^a   Wu, Margaret S ^a   Muise, Eric S ^a   Tan, Yejun ^b   Wood, Harold B ^a   Meinke, Peter T ^a   Thompson, John R ^a   Doebber, Tom W ^a   Berger, Joel P ^a   McCann, Margaret E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ROSETTA INPHARMATICS   (United States)

Author keywords

Adverse cardiovascular effects; Insulin sensitizer; Selective PPAR modulators

Indexed keywords

2 [2 (4 PHENOXY 2 PROPYLPHENOXY)ETHYL]INDOLE 5 ACETIC ACID; 2 [2 CHLORO 5 [[3 (4 CHLOROPHENOXY) 2 METHYL 6 (TRIFLUOROMETHOXY) 1H INDOL 1 YL]METHYL]PHENOXY]PROPIONIC ACID; PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; CARDIOVASCULAR EFFECT; CELL STRAIN 3T3; CELL STRAIN COS1; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SELECTIVITY; FLUID RETENTION; GENE EXPRESSION PROFILING; GLYCEMIC CONTROL; HEART HYPERTROPHY; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; ZUCKER DIABETIC FATTY RAT;

3T3-L1 CELLS; ACETIC ACIDS; ADIPOSE TISSUE, WHITE; ANIMALS; CARDIOMEGALY; CARDIOVASCULAR DISEASES; CERCOPITHECUS AETHIOPS; COS CELLS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMODILUTION; HUMANS; HYPOGLYCEMIC AGENTS; INDOLES; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED STRAINS; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PROPIONATES; PROTEIN BINDING; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES; TRANS-ACTIVATION (GENETICS); TRANSFECTION; WATER-ELECTROLYTE BALANCE;

EID: 41149097453     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.12.036     Document Type: Article

References (40)

1. Actos® package insert. Takeda Pharmaceutical America, Inc., Lincolnshire, IL., USA (2003)
2. Aleo M.D., Lundeen G.R., Blackwell D.K., Smith W.M., Coleman G.L., Stadnicki S.W., and Kluwe W.M. Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-gamma agonist. J. Pharmacol. Exp. Ther. 305 (2003) 1173-1182
3. Avandia® package insert. GlaxoSmithKline, Research Triangle Park, NC, USA (2003)
4. Belcher E.H., and Harriss E.B. Studies of plasma volume, red cell volume and total blood volume in young growing rats. J. Physiol. 139 (1957) 64-78
5. Berger J., Leibowitz M.D., Doebber T.W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C.A., Hayes N.S., Li Y., Tanen M., Ventre J., Wu M.S., Berger G.D., Mosley R., Marquis R., Santini C., Sahoo S.P., Tollman R.L., Smith R.G., and Moller D.E. Novel PPARγ and PPARδ ligands produce distinct biological effects. J. Biol. Chem. 274 (1999) 6718-6725
6. Berger J.P., Petro A.E., Macnaul K.L., Kelly L.J., Zhang B.B., Richards K., Elbrecht A., Johnson B.A., Zhou G., Doebber T.W., Biswas C., Parikh M., Sharma N., Tanen M.R., Thompson G.M., Ventre J., Adams A.D., Mosley R., Surwit R.S., and Moller D.E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. 17 (2003) 662-676
7. Berger J.P., Akiyama T.E., and Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26 (2005) 244-251
8. Burgermeister E., Schnoebelen A., Flament A., Benz J., Stihle M., Gsell B., Rufer A., Ruf A., Kuhn B., Marki H.P., Mizrahi J., Sebokova E., Niesor E., and Meyer M. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. 20 (2006) 809-830
9. Carley A.N., Semeniuk L.M., Shimoni Y., Aasum E., Larsen T.S., Berger J.P., and Severson D.L. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am. J. Physiol: Endocrinol. Metab. 286 (2004) E449-E455
10. Chen L., Yang B., McNulty J.A., Clifton L.G., Binz J.G., Grimes A.M., Strum J.C., Harrington W.W., Chen Z., Balon T.W., Stimpson S.A., and Brown K.K. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J. Pharmacol. Exp. Ther. 312 (2005) 718-725
11. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
12. Cornish B.H., Ward L.C., Thomas B.J., Jebb S.A., and Elia M. Evaluation of multiple frequency bioelectrical impedance and Cole-Cole analysis for the assessment of body water volumes in healthy humans. Eur. J. Clin. Nutr. 50 (1996) 159-164
13. Duan S.Z., Ivashchenko C.Y., Russell M.W., Milstone D.S., and Mortensen R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ. Res. 97 (2005) 372-379
14. Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., and Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142 (2001) 4195-4202
15. Gilde A.J., van der Lee K.A., Willemsen P.H., Chinetti G., van der Leij F.R., van der Vusse G.J., Staels B., and van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 92 (2003) 518-524
16. Guan Y., Zhang Y., Davis L., and Breyer M.D. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am. J. Physiol. 273 (1997) F1013-F1022
17. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., Magnuson M.A., Redha R., Zhang Y., and Breyer M.D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11 (2005) 861-866
18. Hughes T.R., Mao M., Jones A.R., Burchard J., Marton M.J., Shannon K.W., Lefkowitz S.M., Ziman M., Schelter J.M., Meyer M.R., Kobayashi S., Davis C., Dai H., He Y.D., Stephaniants S.B., Cavet G., Walker W.L., West A., Coffey E., Shoemaker D.D., Stoughton R., Blanchard A.P., Friend S.H., and Linsley P.S. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat. Biotechnol. 19 (2001) 342-347
19. Kaplan F., Al-Majali K., and Betteridge D.J. PPARS, insulin resistance and type 2 diabetes. J. Cardiovasc. Risk 8 (2001) 211-217
20. King K.A., and Levi V.E. Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione. Am. J. Health-Syst. Pharm. 61 (2004) 390-393
21. Laplante M., Festuccia W.T., Soucy G., Gelinas Y., Lalonde J., Berger J.P., and Deshaies Y. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 55 (2006) 2771-2778
22. Lebovitz H.E., and Banerji M.A. Insulin resistance and its treatment by thiazolidinediones. Recent Prog. Horm. Res. 56 (2001) 265-294
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
24. Minoura H., Takeshita S., Ita M., Hirosumi J., Mabuchi M., Kawamura I., Nakajima S., Nakayama O., Kayakiri H., Oku T., Ohkubo-Suzuki A., Fukagawa M., Kojo H., Hanioka K., Yamasaki N., Imoto T., Kobayashi Y., and Mutoh S. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur. J. Pharmacol. 494 (2004) 273-281
25. Misra P., Chakrabarti R., Vikramadithyan R.K., Bolusu G., Juluri S., Hiriyan J., Gershome C., Rajjak A., Kashireddy P., Yu S., Surapureddi S., Qi C., Zhu Y.J., Rao M.S., Reddy J.K., and Ramanujam R. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J. Pharmacol. Exp. Ther. 306 (2003) 763-771
26. Mukherjee R., Hoener P.A., Jow L., Bilakovics J., Klausing K., Mais D.E., Faulkner A., Croston G.E., and Paterniti Jr. J.R. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol. Endocrinol. 14 (2000) 1425-1433
27. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., and Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 (2004) 256-263
28. Niemeyer N.V., and Janney L.M. Thiazolidinedione-induced edema. Pharmacotherapy 22 (2002) 924-929
29. Oberfield J.L., Collins J.L., Holmes C.P., Goreham D.M., Cooper J.P., Cobb J.E., Lenhard J.M., Hull-Ryde E.A., Mohr C.P., Blanchard S.G., Parks D.J., Moore L.B., Lehmann J.M., Plunket K., Miller A.B., Milburn M.V., Kliewer S.A., and Willson T.M. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6102-6106
30. Olefsky J.M., and Saltiel A.R. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol. Metab. 11 (2000) 362-368
31. Pickavance L.C., Tadayyon M., Widdowson P.S., Buckingham R.E., and Wilding J.P. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br. J. Pharmacol. 128 (1999) 1570-1576
32. Rezulin® package insert. Warner Lambert Company, Morris Plains, NJ, USA (1997)
33. Rocchi S., Picard F., Vamecq J., Gelman L., Potier N., Zeyer D., Dubuquoy L., Bac P., Champy M.F., Plunket K.D., Leesnitzer L.M., Blanchard S.G., Desreumaux P., Moras D., Renaud J.P., and Auwerx J. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8 (2001) 737-747
34. Rutter K., Hennoste L., Ward L.C., Cornish B.H., and Thomas B.J. Bioelectrical impedance analysis for the estimation of body composition in rats. Lab. Anim. 32 (1998) 65-71
35. Song J., Knepper M.A., Hu X., Verbalis J.G., and Ecelbarger C.A. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J. Pharmacol. Exp. Ther. 308 (2004) 426-433
36. Vidal-Puig A., Jimenez-Linan M., Lowell B.B., Hamann A., Hu E., Spiegelman B., Flier J.S., and Moller D.E. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97 (1996) 2553-2561
37. Werner A.L., and Travaglini M.T. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21 (2001) 1082-1099
38. Yang T., Michele D.E., Park J., Smart A.M., Lin Z., Brosius III F.C., Schnermann J.B., and Briggs J.P. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am. J. Physiol. 277 (1999) F966-F973
39. Zhang B., Berger J., Hu E., Szalkowski D., White-Carrington S., Spiegelman B.M., and Moller D.E. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol. Endocrinol. 10 (1996) 1457-1466
40. Zhang H., Zhang A., Kohan D.E., Nelson R.D., Gonzalez F.J., and Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9406-9411